{"result": "(\"entity\"<|>BENNEDBAEK FN<|>PERSON<|>Bennedbaek FN is an author of a study on the treatment of recurrent thyroid cysts with ethanol, published in J Clin Endocrinol Metab in 2003.)\n##\n(\"entity\"<|>HEGEDÜS L<|>PERSON<|>Hegedüs L is a co-author of the study on the treatment of recurrent thyroid cysts and has contributed to various guidelines in endocrinology.)\n##\n(\"entity\"<|>GHARIB H<|>PERSON<|>Gharib H is a co-author of the American Association of Clinical Endocrinologists guidelines for the diagnosis and management of thyroid nodules.)\n##\n(\"entity\"<|>PAPINI E<|>PERSON<|>Papini E is a co-author of the American Association of Clinical Endocrinologists guidelines and has published on thyroid nodules.)\n##\n(\"entity\"<|>GARBER JR<|>PERSON<|>Garber JR is a co-author of the American Association of Clinical Endocrinologists guidelines for thyroid nodules.)\n##\n(\"entity\"<|>DUICK DS<|>PERSON<|>Duick DS is a co-author of the American Association of Clinical Endocrinologists guidelines for thyroid nodules.)\n##\n(\"entity\"<|>HARRELL RM<|>PERSON<|>Harrell RM is a co-author of the American Association of Clinical Endocrinologists guidelines for thyroid nodules.)\n##\n(\"entity\"<|>HADDAD RI<|>PERSON<|>Haddad RI is a co-author of the NCCN Clinical Practice Guidelines in Oncology for Thyroid Carcinoma.)\n##\n(\"entity\"<|>HAUGEN BR<|>PERSON<|>Haugen BR is a co-author of the American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules.)\n##\n(\"entity\"<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>ORGANIZATION<|>The National Comprehensive Cancer Network provides guidelines for the management of cancer, including thyroid carcinoma.)\n##\n(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association develops guidelines for the management of thyroid nodules and differentiated thyroid cancer.)\n##\n(\"entity\"<|>KOREAN SOCIETY OF THYROID RADIOLOGY<|>ORGANIZATION<|>The Korean Society of Thyroid Radiology provides consensus statements and recommendations for the management of thyroid nodules.)\n##\n(\"entity\"<|>THYROID CANCER<|>EVENT<|>Thyroid cancer is a medical condition that is addressed in various clinical practice guidelines.)\n##\n(\"entity\"<|>THYROID NODULES<|>EVENT<|>Thyroid nodules are a medical condition that is the subject of multiple clinical practice guidelines and studies.)\n##\n(\"relationship\"<|>BENNEDBAEK FN<|>HEGEDÜS L<|>Bennedbaek FN and Hegedüs L co-authored a study on the treatment of recurrent thyroid cysts<|>7)\n##\n(\"relationship\"<|>GHARIB H<|>PAPINI E<|>Gharib H and Papini E co-authored the American Association of Clinical Endocrinologists guidelines for thyroid nodules<|>7)\n##\n(\"relationship\"<|>GARBER JR<|>DUICK DS<|>Garber JR and Duick DS co-authored the American Association of Clinical Endocrinologists guidelines for thyroid nodules<|>7)\n##\n(\"relationship\"<|>HADDAD RI<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>Haddad RI contributed to the NCCN Clinical Practice Guidelines in Oncology for Thyroid Carcinoma<|>8)\n##\n(\"relationship\"<|>HAUGEN BR<|>AMERICAN THYROID ASSOCIATION<|>Haugen BR co-authored the American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules<|>8)\n##\n(\"relationship\"<|>KOREAN SOCIETY OF THYROID RADIOLOGY<|>THYROID NODULES<|>The Korean Society of Thyroid Radiology provides guidelines for the management of thyroid nodules<|>6)\n##\n(\"relationship\"<|>THYROID CANCER<|>THYROID NODULES<|>Thyroid cancer and thyroid nodules are both addressed in clinical practice guidelines<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: opciones B y C. En efecto, la evacuación del contenido quís-                                                            zonas     deficientes     en yodo y que igualmente              se ha    descrito la     presencia de bocio          endémico\n     tico   de   un nódulo      tiroideo    es   una   opción terapéutica           firmemente        establecida      desde     hace                     en áreas suficientes en yodo, lo que sugiere que otros factores ambientales están implicados\n     muchos años          en nódulos puramente quísticos.                                                                                                 en la aparición de bocio. Uno de los factores que se ha implicado es la deficiencia de selenio,\n     Una opción de tratamiento de los nódulos tiroideos son las terapias mínimamente invasi-                                                              oligoelemento que forma parte de las desyodasas que catalizan la transformación periférica\n     vas, como es la ablación por radiofrecuencia u otras tecnologías similares. Sin embargo,                                                             de la T4 en T3 y en T3 reversa              (opción C falsa).\n     antes de indicar estas técnicas es preciso haber demostrado la benignidad del nódulo, para                                                           Finalmente, el estímulo de la TSH siempre se ha considerado el factor que media en la hi-\n     lo que se requiere su estudio citológico previo, incluso en dos ocasiones.                                                                           perplasia tiroidea en respuesta a cualquier factor que pueda dificultar la                               síntesis de hormo-\n     Referencias:                                                                                                                                         nas tiroideas. Una demostración de que la TSH aumenta el tamaño tiroideo es                                       la presencia\n     •  Bennedbaek FN, Hegedüs L. Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial.                          de bocio en los adenomas hipofisarios de TSH. Sin embargo, es                               cierto que en la mayoría de\n        J Clin Endocrinol Metab. 2003;88:5773-7.                                                                                                          los pacientes con bocio los niveles de TSH son normales, habiéndose atribuido a que una\n     •  Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, et al. American Association of Clinical Endocrinologists, American\n        College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and                    deficiencia intratiroidea           de yodo hace al tirocito más sensible al estímulo de la TSH. Por\n        Management of Thyroid Nodules--2016 Update. Endocr Pract. 2016;22:622-39.                                                                         estos motivos se puede considerar falsa la opción D.\n     •  Haddad, RI, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma Version 1.\n        © 2016 National Comprehensive Cancer Network, Inc; 2016. Available at NCCN.org\n     •  Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management                       Referencias:\n        Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines                 • Schlumberger M, Filetti S, Hay ID. In Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia. Cap. 14. 12.ª ed. Williams. Textbook\n        Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.                                                            of Endocrinology. p. 444.\n     •  Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid                  • Brauer V, Schweizer U, Köhrle J, Paschke R. Selenium and goiter prevalence in borderline iodine sufficiency. Eur J Endocrinol.\n        cancers: consensus statement and recommendations. Korean J Radiol. 2012;13:117-25.                                                                  2006;155:807-12.\n     •  Nabhan F, Ringel MD. Thyroid Nodules and Cancer Management Guidelines: Comparisons and Controversies. Endocr Relat Cancer.                        • Liu Y, Huang H, Zeng J, Sun Ch. Thyroid volume, goiter prevalence, and selenium levels in an iodine-sufficient area: a cross-sectional\n        2017;24:R13-26.                                                                                                                                     study. BMC Public Health. 2013;13:1153-59.\n     •  Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer.\n        Clin Endocrinol (Oxf). 2014;81:1-122.\n     •  Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography diagnosis and imaging-based management of thyroid\n        nodules: revised Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol. 2016;17:370-95.\n     •  Verde G, Papini E, Pac\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}